搜索
 > 【B7-1】重组蛋白信息

B7-1信息

英文名称:Cluster of Differentiation 80
中文名称:分化群80
靶点别称:CD80,LAB7,B7,T-lymphocyte activation antigen CD80,CD_antigen=CD80,CTLA-4 counter-receptor B7.1,CD28LG1,CD28LG ,Activation B7-1 antigen,BB1
上市药物数量:2
临床药物数量:14
最高研发阶段:批准上市

B7-1 分子别名

CD80,B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7

B7-1 分子背景

B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response. B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

B7-1 参考文献

B7-1上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Belatacept BMS-224818; LEA29Y; L104EA29YIg; LEA-029 批准上市 百时美施贵宝 NULOJIX fda 器官移植排斥 BRISTOL MYERS SQUIBB 2011-06-15 器官移植排斥, 肾移植排斥反应 详情
Abatacept BMS-188667; ONO-4164; BMS-188667SC; ONO-4164SC,MS188667; ONO4164; BMS188667SC; ONO4164SC 批准上市 百时美施贵宝, 小野制药 ORENCIA fda 类风湿性关节炎, 幼年型类风湿性关节炎 BRISTOL MYERS SQUIBB 2005-12-23 幼年特发性关节炎, 类风湿性关节炎, 幼年型类风湿性关节炎 详情

B7-1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Belatacept biosimilar (Alphamab) KN-019,KN019; KN 019 临床一期 苏州康宁杰瑞生物科技 自身免疫疾病, 肾移植排斥反应
Abatacept biosimilar (Momenta Pharmaceuticals) M-834,M834 临床一期 Momenta, 迈兰制药 自身免疫疾病, 免疫炎症 详情
Recombinant canarypox virus-based vaccine (Sanofi Pasteur) ALVAC-CEA/B7.1 临床二期 赛诺菲巴斯德, Therion Biologics 结肠直肠癌, 黑色素瘤
RG 2077 临床一期 Repligen 糖尿病, 移植物抗宿主病, 系统性红斑狼疮, 多发性硬化症, 类风湿性关节炎, 特发性血小板减少性紫癜 详情
Abatacept biosimilar (Hanwha Biologics) 临床阶段不明 Hanwha Biologics 关节炎
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs 临床一期 湖南昭泰涌仁医疗创新有限公司 非小细胞肺癌
Recombinant human CTLA4-Ig Fusion protein(Shanghai CP Guojian) 临床一期 三生国健药业(上海) 类风湿性关节炎
Galiximab IDEC-114; IDEC-114-20; Anti-B7.1-MAb 临床二期 百健 自身免疫疾病, 银屑病, 非霍奇金淋巴瘤 详情
B7-1 cancer vaccine 临床一期 Nonindustrial source, 伦敦国王学院, 美国国立癌症研究所 急性骨髓性白血病, 卵巢癌, 胰腺癌
Humanized anti-B7 antibodies (Pfizer) 临床二期 辉瑞 移植物抗宿主病, 移植排斥反应
rVV-740CTA vaccine (University Hospital Basel) rVV-740CTA,rVV 740CTA 临床一期 University Hospital Basel 乳腺癌 详情
AV-1142742 AV-1142742 临床二期 Active Biotech, 麦迪金股份公司 自身免疫疾病 详情
ASP-2408 ASP-2408 临床一期 Maxygen, 安斯泰来 类风湿性关节炎 详情
CTLA-4/FasL fusion protein (KAHR Medical) KAHR-102 临床申请 KAHR Medical 淋巴瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定